Avances terapéuticos en el tratamiento del cáncer de ovario: OLAPARIB: primer inhibidor de PARP - page 26

ICON 9:

Assess the efficacy, safety and tolerability of maintenance olaparib in combination

with cediranib compared to maintenance of olaparib alone in patients who have

received combination platinum-based chemotherapy

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,16,17,18,19,20,21,22,23,24,25 27,28,29,30,31,32,33